1
|
Zhao ZX, Zou QY, Ma YH, Morris-Natschke SL, Li XY, Shi LC, Ma GX, Xu XD, Yang MH, Zhao ZJ, Li YX, Xue J, Chen CH, Wu HF. Recent progress on triterpenoid derivatives and their anticancer potential. PHYTOCHEMISTRY 2024; 229:114257. [PMID: 39209239 DOI: 10.1016/j.phytochem.2024.114257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/17/2024] [Revised: 08/19/2024] [Accepted: 08/20/2024] [Indexed: 09/04/2024]
Abstract
Cancer poses a significant global public health challenge, with commonly used adjuvant or neoadjuvant chemotherapy often leading to adverse side effects and drug resistance. Therefore, advancing cancer treatment necessitates the ongoing development of novel anticancer agents with diverse structures and mechanisms of action. Natural products remain crucial in the process of drug discovery, serving as a primary source for pharmaceutical leads and therapeutic advancements. Triterpenoids are particularly compelling due to their complex structures and wide array of biological activities. Recent research has demonstrated that naturally occurring triterpenes and their derivatives have the potential to serve as promising candidates for new drug development. This review aims to comprehensively explore the anticancer properties of triterpenoids and their synthetic analogs, with a focus on recent advancements. Various aspects, such as synthesis, phytochemistry, and molecular simulation for structure-activity relationship analyses, are summarized. It is anticipated that triterpenoid derivatives will emerge as notable anticancer agents following further investigation into their mechanisms of action and in vivo studies.
Collapse
Affiliation(s)
- Zi-Xuan Zhao
- Beijing Key Laboratory of New Drug Discovery Based on Classic Chinese Medicine Prescription, Key Laboratory of Bioactive Substances and Resources Utilization of Chinese Herbal Medicine, Ministry of Education, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100193, China
| | - Qiong-Yu Zou
- Key Laboratory of Research and Utilization of Ethnomedicinal Plant Resources of Hunan Province, Key Laboratory of Hunan Higher Education for Western Hunan Medicinal Plant and Ethnobotany, Hunan Provincial Higher Education Key Laboratory of Intensive Processing Research on Mountain Ecological Food, Key Laboratory of Natural Products Research and Utilization in Wuling Mountain Area, Department of Chemistry & Chemical Engineering, Huaihua University, Huaihua, 418008, China
| | - Ying-Hong Ma
- Beijing Key Laboratory of New Drug Discovery Based on Classic Chinese Medicine Prescription, Key Laboratory of Bioactive Substances and Resources Utilization of Chinese Herbal Medicine, Ministry of Education, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100193, China
| | - Susan L Morris-Natschke
- Natural Products Research Laboratories, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, 27599, USA
| | - Xiang-Yuan Li
- Beijing Key Laboratory of New Drug Discovery Based on Classic Chinese Medicine Prescription, Key Laboratory of Bioactive Substances and Resources Utilization of Chinese Herbal Medicine, Ministry of Education, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100193, China
| | - Lin-Chun Shi
- Beijing Key Laboratory of New Drug Discovery Based on Classic Chinese Medicine Prescription, Key Laboratory of Bioactive Substances and Resources Utilization of Chinese Herbal Medicine, Ministry of Education, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100193, China
| | - Guo-Xu Ma
- Beijing Key Laboratory of New Drug Discovery Based on Classic Chinese Medicine Prescription, Key Laboratory of Bioactive Substances and Resources Utilization of Chinese Herbal Medicine, Ministry of Education, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100193, China
| | - Xu-Dong Xu
- Beijing Key Laboratory of New Drug Discovery Based on Classic Chinese Medicine Prescription, Key Laboratory of Bioactive Substances and Resources Utilization of Chinese Herbal Medicine, Ministry of Education, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100193, China
| | - Mei-Hua Yang
- Beijing Key Laboratory of New Drug Discovery Based on Classic Chinese Medicine Prescription, Key Laboratory of Bioactive Substances and Resources Utilization of Chinese Herbal Medicine, Ministry of Education, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100193, China
| | - Zi-Jian Zhao
- Key Laboratory of Research and Utilization of Ethnomedicinal Plant Resources of Hunan Province, Key Laboratory of Hunan Higher Education for Western Hunan Medicinal Plant and Ethnobotany, Hunan Provincial Higher Education Key Laboratory of Intensive Processing Research on Mountain Ecological Food, Key Laboratory of Natural Products Research and Utilization in Wuling Mountain Area, Department of Chemistry & Chemical Engineering, Huaihua University, Huaihua, 418008, China
| | - Yuan-Xiang Li
- Key Laboratory of Research and Utilization of Ethnomedicinal Plant Resources of Hunan Province, Key Laboratory of Hunan Higher Education for Western Hunan Medicinal Plant and Ethnobotany, Hunan Provincial Higher Education Key Laboratory of Intensive Processing Research on Mountain Ecological Food, Key Laboratory of Natural Products Research and Utilization in Wuling Mountain Area, Department of Chemistry & Chemical Engineering, Huaihua University, Huaihua, 418008, China
| | - Jing Xue
- NHC Key Laboratory of Human Disease Comparative Medicine, Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing, 100021, China.
| | - Chin-Ho Chen
- Antiviral Drug Discovery Laboratory, Surgical Oncology Research Facility, Duke University Medical Center, Durham, NC, 27710, USA.
| | - Hai-Feng Wu
- Beijing Key Laboratory of New Drug Discovery Based on Classic Chinese Medicine Prescription, Key Laboratory of Bioactive Substances and Resources Utilization of Chinese Herbal Medicine, Ministry of Education, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100193, China; Key Laboratory of Research and Utilization of Ethnomedicinal Plant Resources of Hunan Province, Key Laboratory of Hunan Higher Education for Western Hunan Medicinal Plant and Ethnobotany, Hunan Provincial Higher Education Key Laboratory of Intensive Processing Research on Mountain Ecological Food, Key Laboratory of Natural Products Research and Utilization in Wuling Mountain Area, Department of Chemistry & Chemical Engineering, Huaihua University, Huaihua, 418008, China; Natural Products Research Laboratories, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, 27599, USA.
| |
Collapse
|
2
|
Liao CC, Chien CH, Hsu TJ, Li JM. Advancing breastfeeding promotion: leveraging integrative natural galactagogues and unveiling their potential roles-Insights from a 19-year Taiwan nationwide registry to address lactation insufficiency in postpartum women. Front Nutr 2024; 11:1293735. [PMID: 38371501 PMCID: PMC10869601 DOI: 10.3389/fnut.2024.1293735] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2023] [Accepted: 01/15/2024] [Indexed: 02/20/2024] Open
Abstract
Background Lactation insufficiency is a prevalent challenge for nursing mothers globally. There is a growing interest in the use of herbal galactagogues for enhancing lactation, but their therapeutic efficacy and underlying mechanisms need thorough investigation. This study aims to investigate the efficacy and mechanisms of action of herbal galactagogues in addressing lactation insufficiency by utilizing real-world data and employing a network analysis approach. Methods Our retrospective study used Taiwan's Longitudinal Health Insurance Database 2000 (LHID2000) to identify 490 patients diagnosed with lactation insufficiency from 2000 to 2018. We analyzed demographic characteristics, co-existing diseases, and prescription patterns for both users and non-users of Chinese herbal products (CHP). Additionally, we utilized a network analysis approach to explore potential compounds and targets in the most frequently used CHP, the Wang Bu Liu Xing and Lu Lu Tong herb pair (WLHP) combination. Results Out of 490 patients, 81% were CHP users. There were no significant differences in demographic characteristics between CHP users and non-users, but we observed a notable divergence in the prevalence of co-existing diseases. A detailed examination of CHP prescriptions revealed the predominance of WLHP, prompting further investigation. Comprehensive analysis identified 29 major compounds in WLHP, which were associated with 215 unique targets. Intersection analysis revealed 101 overlapping targets between WLHP and lactation, suggesting their potential as therapeutic targets for lactation insufficiency treatment. Topological analysis of the protein-protein interaction (PPI) network identified 13 hub genes potentially crucial for the therapeutic effect of WLHP. Functional enrichment analysis showed that these targets were involved in critical lactation regulation pathways, including the PI3K-Akt signaling pathway, prolactin signaling pathway, estrogen signaling pathway, and AMPK signaling pathway. Discussion This study emphasizes the potential of CHP, specifically the WLHP combination, in managing lactation insufficiency. The multi-compound, multi-target approach of WLHP and its interaction with key biological processes and signaling pathways offer valuable insights into the underlying mechanisms of its therapeutic effects. These findings warrant further experimental validation and can guide future research and clinical applications of CHP in lactation insufficiency treatment.
Collapse
Affiliation(s)
- Chung-Chih Liao
- Department of Post-Baccalaureate Veterinary Medicine, College of Medical and Health Science, Asia University, Taichung, Taiwan
- Chuyuan Chinese Medicine Clinic, Taichung, Taiwan
| | - Chi-Hsien Chien
- Department of Post-Baccalaureate Veterinary Medicine, Asia University, Taichung, Taiwan
| | - Tzu-Ju Hsu
- Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan
| | - Jung-Miao Li
- School of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung, Taiwan
- Department of Chinese Medicine, China Medical University Hospital, Taichung, Taiwan
| |
Collapse
|
3
|
Afrendi E, Prastya ME, Astuti RI, Wahyuni WT, Batubara I. Bioactivity of the Ethanol Extract of Clove ( Syzygium aromaticum) as Antitoxin. INTERNATIONAL JOURNAL OF FOOD SCIENCE 2023; 2023:3245210. [PMID: 37780095 PMCID: PMC10539087 DOI: 10.1155/2023/3245210] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 12/23/2022] [Revised: 06/23/2023] [Accepted: 08/26/2023] [Indexed: 10/03/2023]
Abstract
Toxic compounds can induce the formation of free radicals (reactive oxygen species (ROS)) which can trigger damage and decrease cell viability. Clove (Syzygium aromaticum) contains phenolic compounds that are useful as antioxidants which can reduce ROS toxicity. However, little is known about the antitoxin activity of clove extract. Therefore, this study is aimed at determining the effect of ethanolic clove extract as an antitoxin agent against malachite green (MG) mutagen using the yeast Saccharomyces cerevisiae as a model. The methods used to analyze the ability of ethanolic clove extract as antitoxin were decolorization assay and cell viability test towards MG. The phenol contents of leaf and bud extract were 441.28 and 394.73 mg GAE g-1 extract, respectively. Clove leaf extract has strong antioxidant activity in vitro (IC50 9.29 ppm for 1,1-diphenyl-2-picrylhydrazyl (DPPH) and 29.57 for 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS)). Liquid chromatography quadrupole-mass spectrometry (LC-MS/MS) analysis showed the presence of 4-O-caffeoylquinic acid and several other bioactive compounds, in which these compounds had bioactivity against toxic compound. The addition of extract reduced the ability of S. cerevisiae to decolorize malachite green but increased cell viability. Based on the data, clove leaf extract shows the potential antitoxin activity. This research should facilitate a preliminary study to investigate the antitoxin agent derived from cloves leaf extract. Further research to analyze the antitoxin mechanism of this extract in yeast model is interesting to do to provide a comprehensive insight into the potential antitoxin agents of clove leaf extract.
Collapse
Affiliation(s)
- Erwin Afrendi
- Department of Biology, Dramaga Campus, IPB University, Bogor 16680, Indonesia
| | - Muhammad Eka Prastya
- Research Center for Pharmaceutical Ingredients and Traditional Medicine, National Research and Innovation Agency (BRIN), Kawasan Sains dan Teknologi (KST) B.J Habibie (PUSPIPTEK) Serpong, Tangerang Selatan, Banten 15314, Indonesia
| | - Rika Indri Astuti
- Department of Biology, Dramaga Campus, IPB University, Bogor 16680, Indonesia
- Tropical Biopharmaca Research Center, Bogor Agricultural University, Taman Kencana Street, IPB Taman Kencana Campus, Bogor 16128, Indonesia
| | - Wulan Tri Wahyuni
- Tropical Biopharmaca Research Center, Bogor Agricultural University, Taman Kencana Street, IPB Taman Kencana Campus, Bogor 16128, Indonesia
- Department of Chemistry, Dramaga Campus, IPB University, Bogor 16680, Indonesia
| | - Irmanida Batubara
- Tropical Biopharmaca Research Center, Bogor Agricultural University, Taman Kencana Street, IPB Taman Kencana Campus, Bogor 16128, Indonesia
- Department of Chemistry, Dramaga Campus, IPB University, Bogor 16680, Indonesia
| |
Collapse
|
4
|
Yu W, Zhang Y, Kang C, Zheng Y, Liu X, Liang Z, Yan J. The pharmacological evidence of the chang-yan-ning formula in the treatment of colitis. Front Pharmacol 2022; 13:1029088. [PMID: 36278202 PMCID: PMC9579319 DOI: 10.3389/fphar.2022.1029088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2022] [Accepted: 09/20/2022] [Indexed: 12/08/2022] Open
Abstract
Ulcerative colitis (UC) is a subtype of inflammatory bowel disease (IBD) and occurs mainly in the colon. The etiology of UC is rather complex and involves various pathological factors, including genetic susceptibility, dietary intakes, environment, and microbiota. In China, the Chang-Yan-Ning (CYN) formula has been utilized in the clinic to treat gastrointestinal disorders, but its pharmacological evidence remains elusive. The investigation was designed to explore the molecular and cellular mechanisms of CYN. Liquid Chromatography with tandem mass spectrometry (LC/MS) was performed to identify the key components in the formula; Network pharmacology analysis was executed to predict the potential targets of CYN; An experimental murine colitis model was established by utilizing 2% dextran sodium sulfate (DSS), and CYN was administered for 14 days. The pharmacological mechanism of the CYN formula was corroborated by in-vivo and in-vitro experiments, and high throughput techniques including metabolomics and 16S rRNA sequencing. Results: LC/MS identified the active components in the formula, and network pharmacology analysis predicted 37 hub genes that were involved in tumor necrosis factor (TNF), interleukin (IL)-17, hypoxia-inducible factor (HIF) signaling pathways. As evidenced by in-vivo experiments, DSS administration shortened the length of the colon and led to weight loss, with a compromised structure of epithelium, and the CYN formula reversed these pathological symptoms. Moreover, CYN suppressed the levels of pro-inflammatory cytokines, including IL-4, IL-1b, and TNFαin the serum, inhibited the protein abundance of IL17 and HIF-1αand increased PPARγ and CCL2 in the colon, and facilitated the alternative activation of peritoneal macrophages. While peritoneal macrophages of colitis mice enhanced reactive oxygen species (ROS) production in murine intestinal organoids, the ROS level remained stable co-cultured with the macrophages of CYN-treated mice. Furthermore, the decreased microbiota richness and diversity and the prevalence of pathogenic taxa in colitis mice were rescued after the CYN treatment. The altered metabolic profile during colitis was also restored after the therapy. We posit that the CYN therapy attenuates the development and progression of colitis by maintaining the homeostasis of immune responses and microbiota.
Collapse
|
5
|
Wang S, Yang XX, Li TJ, Zhao L, Bao YR, Meng XS. Analysis of the absorbed constituents and mechanism of liquidambaris fructus extract on hepatocellular carcinoma. Front Pharmacol 2022; 13:999935. [PMID: 36110518 PMCID: PMC9468745 DOI: 10.3389/fphar.2022.999935] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2022] [Accepted: 08/09/2022] [Indexed: 11/13/2022] Open
Abstract
Background: Hepatocellular carcinoma (HCC) refers to one of the top 10 cancers in terms of morbidity and mortality globally, seriously influencing people’s lives. First recorded in Compendium of Materia Medica, liquidambaris fructus (LF) generates definite anti-liver tumor effect. However, its effective substances and mechanism remain to be elucidated.Methods: Serum pharmacochemistry and UPLC-QTOF-MS technologies were employed to explore the plasma of rats after intragastric administration of liquidambaris fructus extract (LFE) in order to find the active ingredients. Subsequently, DEN-induced rat liver cancer model was established with the purpose of investigating the anti-tumor activity of LFE from physiological, pathological and biochemical aspects. Finally, non-target metabonomics combined with q-PCR and Western blot methods were adopted for revealing the mechanism.Results: Totally 11 prototype blood transfused ingredients, including imperatorin and phellopterin were detected. LFE presents excellent impact on enhancing the quality of life, prolonging the life cycle, reducing inflammatory reaction, protecting hepatocytes, improving body immunity and killing liver tumor cells. Altogether 82 endogenous differential metabolites were found in metabonomics, suggesting that LFE can treat HCC by acting on key targets of PTEN/PI3K/Akt pathway and fatty acid metabolism. Further research also verified that LFE can upregulate the relative expression levels of PTEN, PDCD4, Caspase 9, Caspase 3, Bax and Bad as well as lower the relative expression levels of PI3K, AKT, VEGFA and Bcl-2.Conclusion: This study revealed the pharmacodynamic material basis of LFE in the treatment of HCC, and from the perspective of metabolomics proved that the effects of inhibiting the growth of tumor cells, promoting tumor cell apoptosis, reducing inflammatory reaction, protecting hepatocytes, improving the survival state of tumor rats, and prolonging the life cycle are related to its impact on PTEN/PI3K/Akt, fatty acid metabolism and other key signal pathways.
Collapse
Affiliation(s)
- Shuai Wang
- College of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian, China
- Liaoning Multi-Dimensional Analysis of Traditional Chinese Medicine Technical Innovation Center, Dalian, China
- Liaoning Province Modern Chinese Medicine Research Engineering Laboratory, Dalian, China
| | - Xin-Xin Yang
- College of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian, China
- Liaoning Multi-Dimensional Analysis of Traditional Chinese Medicine Technical Innovation Center, Dalian, China
- Liaoning Province Modern Chinese Medicine Research Engineering Laboratory, Dalian, China
| | - Tian-Jiao Li
- College of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian, China
- Liaoning Multi-Dimensional Analysis of Traditional Chinese Medicine Technical Innovation Center, Dalian, China
- Liaoning Province Modern Chinese Medicine Research Engineering Laboratory, Dalian, China
| | - Lin Zhao
- College of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian, China
- Liaoning Multi-Dimensional Analysis of Traditional Chinese Medicine Technical Innovation Center, Dalian, China
- Liaoning Province Modern Chinese Medicine Research Engineering Laboratory, Dalian, China
| | - Yong-Rui Bao
- College of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian, China
- Liaoning Multi-Dimensional Analysis of Traditional Chinese Medicine Technical Innovation Center, Dalian, China
- Liaoning Province Modern Chinese Medicine Research Engineering Laboratory, Dalian, China
- *Correspondence: Yong-Rui Bao, ; Xian-Sheng Meng,
| | - Xian-Sheng Meng
- College of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian, China
- Liaoning Multi-Dimensional Analysis of Traditional Chinese Medicine Technical Innovation Center, Dalian, China
- Liaoning Province Modern Chinese Medicine Research Engineering Laboratory, Dalian, China
- *Correspondence: Yong-Rui Bao, ; Xian-Sheng Meng,
| |
Collapse
|
6
|
Ma TC, Ma YK, Zhang JL, Liu L, Sun J, Guo LN, Liu Q, Sun Y. Integrated Strategy of UHPLC-Q-TOF-MS and Molecular Networking for Identification of Diterpenoids from Euphorbia fischeriana Steud. and Prediction of the Anti-Breast-Cancer Mechanism by the Network Pharmacological Method. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE : ECAM 2021; 2021:3829434. [PMID: 34804177 PMCID: PMC8601799 DOI: 10.1155/2021/3829434] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/19/2021] [Revised: 09/09/2021] [Accepted: 10/15/2021] [Indexed: 11/29/2022]
Abstract
Breast cancer is one of the most common malignancies in women worldwide. Traditional Chinese medicine has been used as adjunctive or complementary therapy for breast cancer. Diterpenoids from Euphorbia fischeriana Steud. have been demonstrated to possess anti-breast-cancer activity. This research was aimed to systematically explore the diterpenoids from E. fischeriana and study the multiple mechanisms on breast cancer. The structures of diterpenoids were identified by the integrated strategy of UHPLC-Q-TOF-MS and molecular networking. A total of 177 diterpenoids belonging to 13 types were collected. In silico ADME analysis was performed on these compounds. It indicated that 130 of 177 diterpenoids completely adjusted to Lipinski's rule. The targets of compounds were obtained from PharmMapper. The targets of breast cancer were collected from GeneCards. Then, 197 compounds-related targets and 544 breast cancer-related targets were identified. After the intersection process, 58 overlapping targets between compounds-related targets and breast cancer-related targets were acquired. The STRING database was applied to predict the protein-protein interactions. The GO and KEGG pathway enrichment analysis were performed by using the KOBAS database. It indicated that these predicted pathways were closely related to breast cancer. The treatment effect of E. fischeriana on breast cancer might be performed through signaling pathways, such as IL-17 signaling pathway, MAPK signaling pathway, and PI3K-Akt signaling pathway. The predicted top genes such as EGFR, ESR, MAPK, SRC, CASP3, CDK2, and KDR were involved in cell proliferation, gene transcription, apoptosis, signal transduction, DNA damage and repair, tumor differentiation, metastasis, and cell cycle, which indicated that E. fischeriana might treat breast cancer comprehensively. A compounds-KEGG pathways-related targets network was built by using cytoHubba to analyze the hub compounds and targets. It concluded that E. fischeriana treated breast cancer not only by the main components but also by the microconstituents, which reflected the overall regulatory role of multicomponents treating breast cancer. To estimate the binding affinities, binding sites, and binding postures, molecular docking simulations between 177 diterpenoids and top 19 targets were carried out. The results are basically in line with expectations. In conclusion, these results can serve as references for researchers studying potential targets of diterpenoids from E. fischeriana on breast cancer in the future.
Collapse
Affiliation(s)
- Tian-Cheng Ma
- Research Institute of Medicine and Pharmacy, Qiqihar Medical University, Bukui Road 333, Qiqihar 161006, Heilongjiang, China
- School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Wenhua Road 103, Shenyang 110016, Liaoning, China
| | - Yu-Kun Ma
- Research Institute of Medicine and Pharmacy, Qiqihar Medical University, Bukui Road 333, Qiqihar 161006, Heilongjiang, China
| | - Jin-Ling Zhang
- Research Institute of Medicine and Pharmacy, Qiqihar Medical University, Bukui Road 333, Qiqihar 161006, Heilongjiang, China
| | - Lei Liu
- Research Institute of Medicine and Pharmacy, Qiqihar Medical University, Bukui Road 333, Qiqihar 161006, Heilongjiang, China
| | - Jia Sun
- Research Institute of Medicine and Pharmacy, Qiqihar Medical University, Bukui Road 333, Qiqihar 161006, Heilongjiang, China
| | - Li-Na Guo
- Research Institute of Medicine and Pharmacy, Qiqihar Medical University, Bukui Road 333, Qiqihar 161006, Heilongjiang, China
| | - Qi Liu
- Research Institute of Medicine and Pharmacy, Qiqihar Medical University, Bukui Road 333, Qiqihar 161006, Heilongjiang, China
| | - Yu Sun
- Research Institute of Medicine and Pharmacy, Qiqihar Medical University, Bukui Road 333, Qiqihar 161006, Heilongjiang, China
| |
Collapse
|
7
|
Li WX, Qian P, Guo YT, Gu L, Jurat J, Bai Y, Zhang DF. Myrtenal and β-caryophyllene oxide screened from Liquidambaris Fructus suppress NLRP3 inflammasome components in rheumatoid arthritis. BMC Complement Med Ther 2021; 21:242. [PMID: 34583676 PMCID: PMC8480017 DOI: 10.1186/s12906-021-03410-2] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2021] [Accepted: 09/15/2021] [Indexed: 12/20/2022] Open
Abstract
Background Liquidambaris Fructus (LF) is the infructescence of Liquidambar formosana. In Traditional Chinese Medicine, LF has been used to treat joint pain, a common symptom of arthritis and rheumatism; however, a lack of pharmacological evidence has limited its applications in modern clinics. Therefore, this study aims to explore the protective effect of LF on rheumatoid arthritis (RA) and to identify its active ingredients. Methods Rats with adjuvant-induced arthritis (AIA) were divided into 4 groups and administered petroleum ether extract of LF (PEL), ethyl acetate extract of LF (EEL), water extract of LF (WEL), or piroxicam (PIR) respectively for 3 weeks. Two additional groups were used as normal control (NC) and model control (MC) and administered distilled water as a placebo. The clinical scores for arthritis, bone surface, synovial inflammation and cartilage erosion were used to evaluate the therapeutic efficacy of each treatment. The serum IL-1β and TNF-α level and the expression of NLRP3, IL-1β and caspase-1 p20 in the synovial tissue of AIA rats were evaluated by ELISA and Western blot. The active ingredients of LF were investigated using network pharmacology and molecular docking methods, and their inhibition of NLRP3 inflammasome activation was verified in the human rheumatoid arthritis fibroblast-like synovial cells (RA-FLS) model. Results PEL could alleviate paw swelling, bone and joint destruction, synovial inflammation and cartilage erosion in the AIA rats, with significantly superior efficacy to that of EEL and WEL. PEL reduced IL-1β and TNF-α serum levels, and attenuated the upregulation of NLRP3, IL-1β and caspase-1 p20 expression in the synovial tissue of AIA rats. Network pharmacology and molecular docking results indicated that myrtenal and β-caryophyllene oxide were the main two active ingredients of PEL, and these two compounds showed significant inhibition on TNF-α, NLRP3, IL-1β and caspase-1 p20 expression in RA-FLS. Conclusions Myrtenal and β-caryophyllene oxide screened from PEL could suppress the activation of NLRP3 inflammasome, thereby alleviating RA symptoms. Supplementary Information The online version contains supplementary material available at 10.1186/s12906-021-03410-2.
Collapse
Affiliation(s)
- Wen-Xuan Li
- Department of Pharmacognosy, School of Pharmacy, China Medical University, Shenyang, 110122, Liaoning, China
| | - Ping Qian
- Department of Pharmacognosy, School of Pharmacy, China Medical University, Shenyang, 110122, Liaoning, China
| | - Yi-Tong Guo
- Department of Pharmacognosy, School of Pharmacy, China Medical University, Shenyang, 110122, Liaoning, China
| | - Li Gu
- Department of Pharmacognosy, School of Pharmacy, China Medical University, Shenyang, 110122, Liaoning, China
| | - Jessore Jurat
- Department of Pharmacognosy, School of Pharmacy, China Medical University, Shenyang, 110122, Liaoning, China
| | - Yang Bai
- Department of Clinical Pharmacology, School of Pharmacy, China Medical University, Shenyang, 110122, Liaoning, China.
| | - Dong-Fang Zhang
- Department of Pharmacognosy, School of Pharmacy, China Medical University, Shenyang, 110122, Liaoning, China.
| |
Collapse
|
8
|
Ahmadu AA, Delehouzé C, Haruna A, Mustapha L, Lawal BA, Udobre A, Baratte B, Triscornia C, Autret A, Robert T, Bulinski JC, Rousselot M, Simoes Eugénio M, Dimanche-Boitrel MT, Petzer JP, Legoabe LJ, Bach S. Betulin, a Newly Characterized Compound in Acacia auriculiformis Bark, Is a Multi-Target Protein Kinase Inhibitor. Molecules 2021; 26:molecules26154599. [PMID: 34361750 PMCID: PMC8347092 DOI: 10.3390/molecules26154599] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2021] [Revised: 07/26/2021] [Accepted: 07/27/2021] [Indexed: 02/03/2023] Open
Abstract
The purpose of this work is to investigate the protein kinase inhibitory activity of constituents from Acacia auriculiformis stem bark. Column chromatography and NMR spectroscopy were used to purify and characterize betulin from an ethyl acetate soluble fraction of acacia bark. Betulin, a known inducer of apoptosis, was screened against a panel of 16 disease-related protein kinases. Betulin was shown to inhibit Abelson murine leukemia viral oncogene homolog 1 (ABL1) kinase, casein kinase 1ε (CK1ε), glycogen synthase kinase 3α/β (GSK-3 α/β), Janus kinase 3 (JAK3), NIMA Related Kinase 6 (NEK6), and vascular endothelial growth factor receptor 2 kinase (VEGFR2) with activities in the micromolar range for each. The effect of betulin on the cell viability of doxorubicin-resistant K562R chronic myelogenous leukemia cells was then verified to investigate its putative use as an anti-cancer compound. Betulin was shown to modulate the mitogen-activated protein (MAP) kinase pathway, with activity similar to that of imatinib mesylate, a known ABL1 kinase inhibitor. The interaction of betulin and ABL1 was studied by molecular docking, revealing an interaction of the inhibitor with the ABL1 ATP binding pocket. Together, these data demonstrate that betulin is a multi-target inhibitor of protein kinases, an activity that can contribute to the anticancer properties of the natural compound and to potential treatments for leukemia.
Collapse
Affiliation(s)
- Augustine A. Ahmadu
- Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmaceutical Sciences, Kaduna State University, Kaduna 800241, Nigeria; (A.H.); (L.M.)
- Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmacy, University of Calabar, Calabar 540271, Nigeria
- Correspondence: (A.A.A.); (S.B.); Tel.: +234-80-37-03-35-05 (A.A.A.); +33-2-98-29-23-91 (S.B.)
| | - Claire Delehouzé
- Station Biologique de Roscoff, CNRS, UMR8227, Integrative Biology of Marine Models Laboratory (LBI2M), Sorbonne Université, 29680 Roscoff, France; (C.D.); (B.B.); (C.T.); (T.R.); (J.C.B.)
- Place Georges Teissier, SeaBeLife Biotech, 29680 Roscoff, France; (A.A.); (M.R.); (M.S.E.)
| | - Anas Haruna
- Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmaceutical Sciences, Kaduna State University, Kaduna 800241, Nigeria; (A.H.); (L.M.)
| | - Lukman Mustapha
- Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmaceutical Sciences, Kaduna State University, Kaduna 800241, Nigeria; (A.H.); (L.M.)
| | - Bilqis A. Lawal
- Department of Pharmacognosy and Drug Development, Faculty of Pharmaceutical Sciences, University of Ilorin, Ilorin 240003, Nigeria;
| | - Aniefiok Udobre
- Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmacy, University of Uyo, Uyo 520003, Nigeria;
| | - Blandine Baratte
- Station Biologique de Roscoff, CNRS, UMR8227, Integrative Biology of Marine Models Laboratory (LBI2M), Sorbonne Université, 29680 Roscoff, France; (C.D.); (B.B.); (C.T.); (T.R.); (J.C.B.)
- CNRS, FR2424, Station Biologique de Roscoff, Plateforme de Criblage KISSf (Kinase Inhibitor Specialized Screening Facility), Sorbonne Université, 29680 Roscoff, France
| | - Camilla Triscornia
- Station Biologique de Roscoff, CNRS, UMR8227, Integrative Biology of Marine Models Laboratory (LBI2M), Sorbonne Université, 29680 Roscoff, France; (C.D.); (B.B.); (C.T.); (T.R.); (J.C.B.)
| | - Axelle Autret
- Place Georges Teissier, SeaBeLife Biotech, 29680 Roscoff, France; (A.A.); (M.R.); (M.S.E.)
| | - Thomas Robert
- Station Biologique de Roscoff, CNRS, UMR8227, Integrative Biology of Marine Models Laboratory (LBI2M), Sorbonne Université, 29680 Roscoff, France; (C.D.); (B.B.); (C.T.); (T.R.); (J.C.B.)
- CNRS, FR2424, Station Biologique de Roscoff, Plateforme de Criblage KISSf (Kinase Inhibitor Specialized Screening Facility), Sorbonne Université, 29680 Roscoff, France
| | - Jeannette Chloë Bulinski
- Station Biologique de Roscoff, CNRS, UMR8227, Integrative Biology of Marine Models Laboratory (LBI2M), Sorbonne Université, 29680 Roscoff, France; (C.D.); (B.B.); (C.T.); (T.R.); (J.C.B.)
- Department of Biological Sciences, Columbia University, New York, NY 10027, USA
| | - Morgane Rousselot
- Place Georges Teissier, SeaBeLife Biotech, 29680 Roscoff, France; (A.A.); (M.R.); (M.S.E.)
| | - Mélanie Simoes Eugénio
- Place Georges Teissier, SeaBeLife Biotech, 29680 Roscoff, France; (A.A.); (M.R.); (M.S.E.)
- Institut de Recherche sur la Santé, l’Environnement et le Travail (IRSET), INSERM UMR 1085, F-35043 Rennes, France;
| | - Marie-Thérèse Dimanche-Boitrel
- Institut de Recherche sur la Santé, l’Environnement et le Travail (IRSET), INSERM UMR 1085, F-35043 Rennes, France;
- Biosit UMS 3080, Université de Rennes 1, F-35043 Rennes, France
| | - Jacobus P. Petzer
- Centre of Excellence for Pharmaceutical Sciences, North-West University, Private Bag X6001, Potchefstroom 2520, South Africa; (J.P.P.); (L.J.L.)
- Pharmaceutical Chemistry, School of Pharmacy, North-West University, Private Bag X6001, Potchefstroom 2520, South Africa
| | - Lesetja J. Legoabe
- Centre of Excellence for Pharmaceutical Sciences, North-West University, Private Bag X6001, Potchefstroom 2520, South Africa; (J.P.P.); (L.J.L.)
| | - Stéphane Bach
- Station Biologique de Roscoff, CNRS, UMR8227, Integrative Biology of Marine Models Laboratory (LBI2M), Sorbonne Université, 29680 Roscoff, France; (C.D.); (B.B.); (C.T.); (T.R.); (J.C.B.)
- CNRS, FR2424, Station Biologique de Roscoff, Plateforme de Criblage KISSf (Kinase Inhibitor Specialized Screening Facility), Sorbonne Université, 29680 Roscoff, France
- Centre of Excellence for Pharmaceutical Sciences, North-West University, Private Bag X6001, Potchefstroom 2520, South Africa; (J.P.P.); (L.J.L.)
- Correspondence: (A.A.A.); (S.B.); Tel.: +234-80-37-03-35-05 (A.A.A.); +33-2-98-29-23-91 (S.B.)
| |
Collapse
|